[go: up one dir, main page]

RU2539595C2 - Изоксазолины в качестве ингибиторов амидгидролазы жирных кислот - Google Patents

Изоксазолины в качестве ингибиторов амидгидролазы жирных кислот Download PDF

Info

Publication number
RU2539595C2
RU2539595C2 RU2011151635/04A RU2011151635A RU2539595C2 RU 2539595 C2 RU2539595 C2 RU 2539595C2 RU 2011151635/04 A RU2011151635/04 A RU 2011151635/04A RU 2011151635 A RU2011151635 A RU 2011151635A RU 2539595 C2 RU2539595 C2 RU 2539595C2
Authority
RU
Russia
Prior art keywords
alkyl
compound
substituted
group
groups
Prior art date
Application number
RU2011151635/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2011151635A (ru
Inventor
Марк Л. БЕНКЕ
Альфредо С. КАСТРО
Лоуренс К. ЧАН
Кэтрин А. ЭВАНС
Луи ГРЕНЬЕ
Майкл Дж. ГРОГАН
Ив Леблан
Тао ЛЮ
Стефан ПЕЛЮЗО
Дэниел А. СНАЙДЕР
Томас Т. ТИББИТТС
Original Assignee
Инфинити Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Инфинити Фармасьютикалз, Инк. filed Critical Инфинити Фармасьютикалз, Инк.
Publication of RU2011151635A publication Critical patent/RU2011151635A/ru
Application granted granted Critical
Publication of RU2539595C2 publication Critical patent/RU2539595C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
RU2011151635/04A 2009-05-18 2010-05-18 Изоксазолины в качестве ингибиторов амидгидролазы жирных кислот RU2539595C2 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US17928509P 2009-05-18 2009-05-18
US17928309P 2009-05-18 2009-05-18
US17928009P 2009-05-18 2009-05-18
US61/179,280 2009-05-18
US61/179,285 2009-05-18
US61/179,283 2009-05-18
PCT/US2010/035309 WO2010135360A1 (fr) 2009-05-18 2010-05-18 Isoxazolines en tant qu'inhibiteurs de l'hydrolase des amides d'acides gras

Publications (2)

Publication Number Publication Date
RU2011151635A RU2011151635A (ru) 2013-06-27
RU2539595C2 true RU2539595C2 (ru) 2015-01-20

Family

ID=43126477

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2011151635/04A RU2539595C2 (ru) 2009-05-18 2010-05-18 Изоксазолины в качестве ингибиторов амидгидролазы жирных кислот

Country Status (16)

Country Link
EP (1) EP2432771A4 (fr)
JP (1) JP2012527467A (fr)
KR (1) KR20120042766A (fr)
CN (1) CN102459202B (fr)
AR (1) AR076687A1 (fr)
AU (1) AU2010249674A1 (fr)
BR (1) BRPI1011049A2 (fr)
CA (1) CA2762527A1 (fr)
IL (1) IL216420A0 (fr)
MX (1) MX2011012263A (fr)
NZ (2) NZ619076A (fr)
RU (1) RU2539595C2 (fr)
SG (2) SG176168A1 (fr)
TW (1) TW201043620A (fr)
WO (1) WO2010135360A1 (fr)
ZA (1) ZA201108657B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12178804B2 (en) 2018-09-13 2024-12-31 Syneurx International (Taiwan) Corp. Salts of cycloserine compounds and applications thereof

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2666219C (fr) 2006-10-16 2017-02-07 Bionomics Limited Nouveaux composes anxiolytiques
US10954231B2 (en) 2006-10-16 2021-03-23 Bionomics Limited Anxiolytic compounds
US8927551B2 (en) 2009-05-18 2015-01-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US9149465B2 (en) 2009-05-18 2015-10-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
WO2011085216A2 (fr) 2010-01-08 2011-07-14 Ironwood Pharmaceuticals, Inc. Utilisation d'inhibiteurs de faah pour traiter la maladie de parkinson et le syndrome des jambes sans repos
US20130224151A1 (en) 2010-03-31 2013-08-29 United States Of America Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain
CN103502219A (zh) 2011-03-02 2014-01-08 生态学有限公司 作为治疗剂的新型小分子
EP2707367B1 (fr) 2011-05-12 2019-10-09 Bionomics Limited Procédés pour la préparation de naphtyridines
WO2018112843A1 (fr) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Modulateurs allostériques d'éther hétéroarylpipéridine du récepteur muscarinique de l'acétylcholine m4
MX2020001615A (es) 2017-08-10 2020-07-13 Taisho Pharmaceutical Co Ltd Compuestos de piridina sustituidos con azol.
CA3113823A1 (fr) * 2018-10-15 2020-04-23 Dana-Farber Cancer Institute, Inc. Inhibiteurs du facteur de transcription a domaine associe transcriptionnel ameliore (tead) et leurs utilisations
CN110016142B (zh) * 2019-04-30 2021-08-03 合肥工业大学 一种含嘧啶硼酸结构的硅油及其制备方法
WO2020243423A1 (fr) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Inhibiteurs de tead et leurs utilisations
CA3142351A1 (fr) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Inhibiteurs de tead et leurs utilisations
US20240140917A1 (en) 2021-02-11 2024-05-02 Basf Se Substituted isoxazoline derivatives
EP4043444A1 (fr) 2021-02-11 2022-08-17 Basf Se Dérivés substitués d'isoxazoline
CN116888101A (zh) * 2021-02-11 2023-10-13 巴斯夫欧洲公司 取代的异噁唑啉衍生物
IL312330A (en) 2021-10-25 2024-06-01 Kymera Therapeutics Inc Tyk2 degraders and uses thereof
EP4238971A1 (fr) 2022-03-02 2023-09-06 Basf Se Dérivés substitués d'isoxazoline
WO2023165854A1 (fr) 2022-03-02 2023-09-07 Basf Se Dérivés d'isoxazoline substitués
EP4590665A1 (fr) 2022-09-20 2025-07-30 Basf Se Dérivés de n-(3-(aminométhyl)-phényl)-5-(4-phényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-amine et composés similaires utilisés comme pesticides
EP4342885A1 (fr) 2022-09-20 2024-03-27 Basf Se Dérivés de n-(3-(aminométhyl)-phényl)-5-(4-phényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-amine et composés similaires en tant que pesticides

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070155747A1 (en) * 2005-12-29 2007-07-05 Kadmus Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
EP1813606A1 (fr) * 2004-11-18 2007-08-01 Takeda Pharmaceutical Company Limited Composé amide
RU2331637C2 (ru) * 2004-02-26 2008-08-20 Санофи-Авентис Производные алкилпиперазин- и алкилгомопиперазинкарбоксилатов, их получение и применение в качестве ингибиторов фермента faah
WO2009011904A1 (fr) * 2007-07-19 2009-01-22 Renovis, Inc. Composés utiles comme modulateurs de la faah et utilisation de ceux-ci

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9505651D0 (en) * 1995-03-21 1995-05-10 Agrevo Uk Ltd AgrEvo UK Limited
CA2501575A1 (fr) * 2002-10-08 2004-04-22 The Scripps Research Institute Inhibiteurs d'amide hydrolase d'acide gras
WO2004044169A2 (fr) * 2002-11-14 2004-05-27 The Scripps Research Institute Forme cristalline de l'amine hydrolase d'acide gras (faah)
WO2005034952A2 (fr) * 2003-10-07 2005-04-21 The Feinstein Institute For Medical Research Composes anti-inflammatoires
ITMI20061279A1 (it) * 2006-06-30 2008-01-01 Consiglio Nazionale Ricerche Agonisti nicotinici selettivi per il sottotipo recettoriale alfa7,procedimento per la loro preparazione e relative composizioni farmaceutiche
JO3598B1 (ar) * 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
CN101959881A (zh) * 2007-12-27 2011-01-26 比艾尔-坡特拉有限公司 用于医疗用途的5-o-取代3-n-苯基-1,3,4-噁二唑酮
KR20150065958A (ko) * 2008-01-25 2015-06-15 이 아이 듀폰 디 네모아 앤드 캄파니 살균제 복소환 화합물

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2331637C2 (ru) * 2004-02-26 2008-08-20 Санофи-Авентис Производные алкилпиперазин- и алкилгомопиперазинкарбоксилатов, их получение и применение в качестве ингибиторов фермента faah
EP1813606A1 (fr) * 2004-11-18 2007-08-01 Takeda Pharmaceutical Company Limited Composé amide
US20070155747A1 (en) * 2005-12-29 2007-07-05 Kadmus Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
WO2009011904A1 (fr) * 2007-07-19 2009-01-22 Renovis, Inc. Composés utiles comme modulateurs de la faah et utilisation de ceux-ci

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12178804B2 (en) 2018-09-13 2024-12-31 Syneurx International (Taiwan) Corp. Salts of cycloserine compounds and applications thereof

Also Published As

Publication number Publication date
SG176168A1 (en) 2011-12-29
SG10201402443PA (en) 2014-10-30
NZ619076A (en) 2015-07-31
EP2432771A1 (fr) 2012-03-28
TW201043620A (en) 2010-12-16
JP2012527467A (ja) 2012-11-08
IL216420A0 (en) 2012-03-01
CA2762527A1 (fr) 2010-11-25
NZ596585A (en) 2014-01-31
KR20120042766A (ko) 2012-05-03
CN102459202A (zh) 2012-05-16
RU2011151635A (ru) 2013-06-27
ZA201108657B (en) 2013-01-30
CN102459202B (zh) 2015-11-25
WO2010135360A1 (fr) 2010-11-25
MX2011012263A (es) 2012-01-30
AU2010249674A1 (en) 2011-12-15
EP2432771A4 (fr) 2013-06-05
BRPI1011049A2 (pt) 2019-09-24
AR076687A1 (es) 2011-06-29

Similar Documents

Publication Publication Date Title
RU2539595C2 (ru) Изоксазолины в качестве ингибиторов амидгидролазы жирных кислот
JP5710805B2 (ja) 脂肪酸アミドヒドロラーゼのインヒビター
JP5637982B2 (ja) 脂肪酸アミド加水分解酵素の阻害剤
KR102486298B1 (ko) 인돌아민-2,3-디옥시게나아제(ido)의 억제제
US9102697B2 (en) Trioxacarcins and uses thereof
JP7643874B2 (ja) がん幹細胞を標的化するがん治療
JP2010505955A5 (fr)
US9149465B2 (en) Isoxazolines as inhibitors of fatty acid amide hydrolase
US8927551B2 (en) Isoxazolines as inhibitors of fatty acid amide hydrolase
US8765735B2 (en) Isoxazolines as inhibitors of fatty acid amide hydrolase
CA3001882A1 (fr) Sulfonamides de polyamine et leurs utilisations
WO2025151874A1 (fr) Agents antiplasmodiques alcaloïdes indoliques et leur préparation
US20200062776A1 (en) Hedgehog acyltransferase inhibitors and uses thereof
HK40057874A (zh) 吲哚胺-2，3-双加氧酶(ido)抑制剂
HK40000485A (en) Inhibitor of indoleamine-2,3-dioxygenase (ido)
TW201028416A (en) 2-aza-bicyclo[2.2.2]octane compounds and uses thereof

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20160519